{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:46:09Z","timestamp":1793666769279,"version":"4.5.1"},"reference-count":117,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cell immunotherapy has changed the landscape of B cell hematological malignancies\u2019 management, while it has recently shown promising results in the treatment of refractory autoimmune rheumatic disorders (ARDs). Targeting B cell antigens such as CD19 and BCMA, CAR-T cell therapy can induce sustained remission by the elimination of autoreactive B cell populations resistant to the standard of care treatment options. Clinical data from case reports and small case series demonstrate profound clinical responses in ARDs, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs), rheumatoid arthritis (RA), antiphospholipid syndrome (APS), and primary Sj\u00f6gren\u2019s syndrome (pSS). Treatment outcomes include reduced disease activity, normalization of serologic markers, improved organ function, and drug-free remission, even after B cell reconstitution. Additionally, toxicities, primarily limited to mild cytokine release syndrome (CRS), were generally manageable with supportive care. Encouraging preliminary results have led to the development of several ongoing clinical trials investigating CAR-T cell therapy across multiple ARDs and patient populations, including pediatric patients. This review summarizes the current clinical experience and provides a comprehensive overview of ongoing clinical trials exploring CAR-T cell immunotherapy for ARDs.<\/jats:p>","DOI":"10.3390\/cells14161242","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:51:02Z","timestamp":1755013862000},"page":"1242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-4629","authenticated-orcid":false,"given":"Panagiota","family":"Anyfanti","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-5111","authenticated-orcid":false,"given":"Paschalis","family":"Evangelidis","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2919-5179","authenticated-orcid":false,"given":"Nikolaos","family":"Kotsiou","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-155X","authenticated-orcid":false,"given":"Anna","family":"Papakonstantinou","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Eftychidis","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Sakellari","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1642","authenticated-orcid":false,"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Vukovic, J., Abazovic, D., Vucetic, D., and Medenica, S. (2024). CAR-Engineered T Cell Therapy as an Emerging Strategy for Treating Autoimmune Diseases. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1447147"},{"key":"ref_2","first-page":"802","article-title":"CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","volume":"14","author":"Davila","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Goyco Vera, D., Waghela, H., Nuh, M., Pan, J., and Lulla, P. (2024). Approved CAR-T Therapies Have Reproducible Efficacy and Safety in Clinical Practice. Hum. Vaccin. Immunother., 20.","DOI":"10.1080\/21645515.2024.2378543"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-Targeted Immunotherapy for Multiple Myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T Therapies in Multiple Myeloma: Unleashing the Future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Evangelidis, P., Tragiannidis, K., Vyzantiadis, A., Evangelidis, N., Kalmoukos, P., Vyzantiadis, T.-A., Tragiannidis, A., Kourti, M., and Gavriilaki, E. (2025). Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients. Pathogens, 14.","DOI":"10.3390\/pathogens14020170"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Strongyli, E., Evangelidis, P., Sakellari, I., Gavriilaki, M., and Gavriilaki, E. (2024). Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb. Pharmaceuticals, 17.","DOI":"10.3390\/ph17050591"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Sakellari, I., Gavriilaki, M., and Anagnostopoulos, A. (2020). A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113886"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T Cell Therapy\u2013Related Cardiovascular Outcomes and Management","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100186","DOI":"10.1016\/j.tru.2024.100186","article-title":"Thrombotic Complications after Hematopoietic Stem Cell Transplantation and Other Cellular Therapies","volume":"16","author":"Evangelidis","year":"2024","journal-title":"Thromb. Update"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the Beast: CRS and ICANS after CAR T-Cell Therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3390\/cimb46050288","article-title":"Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill","volume":"46","author":"Evangelidis","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_14","first-page":"2430","article-title":"How I Treat Refractory CRS and ICANS Following CAR T-Cell Therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, Prevalence, and Co-Occurrence of Autoimmune Disorders over Time and by Age, Sex, and Socioeconomic Status: A Population-Based Cohort Study of 22 Million Individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.2147\/JIR.S276986","article-title":"Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases","volume":"14","author":"Anyfanti","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Moutsopoulos, H.M. (2021). Autoimmune Rheumatic Diseases: One or Many Diseases?. J. Transl. Autoimmun., 4.","DOI":"10.1016\/j.jtauto.2021.100129"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.31138\/mjr.28.2.75","article-title":"Regulatory B Cells in Autoimmune Rheumatic Diseases","volume":"28","author":"Sakkas","year":"2017","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.31138\/mjr.310824.cri","article-title":"Cardiovascular Risk in Rheumatoid Arthritis: Considerations on Assessment and Management","volume":"35","author":"Anyfanti","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sureda, A., Corbacioglu, S., Greco, R., Kr\u00f6ger, N., and Carreras, E. (2024). The EBMT Handbook, Springer International Publishing.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic Lupus Erythematosus: Updated Insights on the Pathogenesis, Diagnosis, Prevention and Therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41584-024-01152-2","article-title":"Systemic Lupus Erythematosus Genetics: Insights into Pathogenesis and Implications for Therapy","volume":"20","author":"Olferiev","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease-A Case Series with Follow-Up","volume":"390","author":"Taubmann","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/S0140-6736(24)02265-7","article-title":"Treatment of CNS Systemic Lupus Erythematosus with CD19 CAR T Cells","volume":"404","author":"Hagen","year":"2024","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of Systemic Lupus Erythematosus Using BCMA-CD19 Compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"He, X., Hu, B., Zhang, Y., Liu, F., Li, Q., Zheng, C., Shen, J., Yang, Z., Wang, J., and Ma, D. (2025). Treatment of Two Pediatric Patients with Refractory Systemic Lupus Erythematosus Using CD19-Targeted CAR T-Cells. Autoimmun. Rev., 24.","DOI":"10.1016\/j.autrev.2024.103692"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic Sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2174\/13816128113199990555","article-title":"Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease","volume":"20","author":"Dimitroulas","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a Patient with Severe Systemic Sclerosis (SSc) Using CD19-Targeted CAR T Cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-Targeting CAR T-Cell Therapy in Patients with Diffuse Systemic Sclerosis: A Case Series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-Generation CD19.CAR-T Cell-Containing Combination Therapy in Scl70+ Systemic Sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1871528113666140131151522","article-title":"Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance","volume":"13","author":"Mavrogeni","year":"2014","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Szabo, D., Balogh, A., Gopcsa, L., Giba-Kiss, L., Lakatos, G., Paksi, M., Reti, M., Takacs, P., van Heteren, P., and Zadoyan, G. (2024). Sustained Drug-Free Remission in Rheumatoid Arthritis Associated with Diffuse Large B-Cell Lymphoma Following Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cell Therapy Using Zamtocabtagene Autoleucel. RMD Open, 10.","DOI":"10.1136\/rmdopen-2024-004727"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1871528113666140526162640","article-title":"Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging","volume":"13","author":"Mavrogeni","year":"2014","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-Targeted CAR T Cells in Refractory Antisynthetase Syndrome","volume":"401","author":"Boeltz","year":"2023","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case Study of CD19 CAR T Therapy in a Subject with Immune-Mediate Necrotizing Myopathy Treated in the RESET-Myositis Phase I\/II Trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","article-title":"Disappearance of Antiphospholipid Antibodies after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphoma in a Patient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome","volume":"23","author":"Friedberg","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Schmelz, J.L., Navsaria, L., Goswamy, R., Chuang, H.H., Miranda, R.N., and Lee, H.J. (2020). Chimeric Antigen Receptor T-cell Therapy\u2019s Role in Antiphospholipid Syndrome: A Case Report. Br. J. Haematol., 188.","DOI":"10.1111\/bjh.16266"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41584-024-01135-3","article-title":"Update on the Pathophysiology and Treatment of Primary Sj\u00f6gren Syndrome","volume":"20","author":"Baldini","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sheng, L., Zhang, Y., Song, Q., Jiang, X., Cao, W., Li, L., Yi, H., Weng, X., Chen, S., and Wang, Z. (2023). Concurrent Remission of Lymphoma and Sj\u00f6gren\u2019s Disease Following Anti-CD19 Chimeric Antigen Receptor-T Cell Therapy for Diffuse Large B-Cell Lymphoma: A Case Report. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1298815"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1097\/MS9.0000000000000891","article-title":"Chimeric Antigen Receptor T Cell Therapy for the Treatment of Systemic Rheumatic Diseases: A Comprehensive Review of Recent Literature","volume":"85","author":"Bhandari","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/rheumatology\/kex265","article-title":"Predictors and Long-Term Outcome in Greek Adults with Juvenile Idiopathic Arthritis: A 17-Year Continuous Follow-up Study","volume":"56","author":"Dimopoulou","year":"2017","journal-title":"Rheumatology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Par\u00eds-Mu\u00f1oz, A., Alcobendas-Rueda, R.M., Verd\u00fa-S\u00e1nchez, C., Udaondo, C., Gal\u00e1n-G\u00f3mez, V., Gonz\u00e1lez-Mart\u00ednez, B., Men\u00e9ndez, J.J., Mart\u00ednez-Romera, I., Minguill\u00f3n, J., and Pert\u00ed\u00f1ez, L. (2025). CD19 CAR-T Cell Therapy in a Pediatric Patient with MDA5+ Dermatomyositis and Rapidly Progressive Interstitial Lung Disease. Med.","DOI":"10.1016\/j.medj.2025.100676"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0167-5699(94)90274-7","article-title":"The CD19\/CD21 Signal Transduction Complex of B Lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.immunol.18.1.393","article-title":"Regulation of B Lymphocyte Responses to Foreign and Self-Antigens by the CD19\/CD21 Complex","volume":"18","author":"Fearon","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The Generation of Antibody-Secreting Plasma Cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/10409238.2016.1215288","article-title":"The PI3K Pathway in B Cell Metabolism","volume":"51","author":"Jellusova","year":"2016","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Komura, K. (2024). CD19: A Promising Target for Systemic Sclerosis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1454913"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.20674","article-title":"Association of a Functional CD19 Polymorphism with Susceptibility to Systemic Sclerosis","volume":"50","author":"Tsuchiya","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI0215078","article-title":"CD19-Dependent B Lymphocyte Signaling Thresholds Influence Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse","volume":"109","author":"Saito","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Reijm, S., Kwekkeboom, J.C., Blomberg, N.J., Suurmond, J., van der Woude, D., Toes, R.E.M., and Scherer, H.U. (2023). Autoreactive B Cells in Rheumatoid Arthritis Include Mainly Activated CXCR3+ Memory B Cells and Plasmablasts. JCI Insight, 8.","DOI":"10.1172\/jci.insight.172006"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.110.168062","article-title":"B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody","volume":"335","author":"Herbst","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2\/3 Trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.172.6.3422","article-title":"Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?","volume":"172","author":"Duddy","year":"2004","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Chu, S.Y., Pong, E., Bonzon, C., Yu, N., Jacob, C.O., Chalmers, S.A., Putterman, C., Szymkowski, D.E., and Stohl, W. (2021). Inhibition of B Cell Activation Following in Vivo Co-Engagement of B Cell Antigen Receptor and Fc\u03b3 Receptor IIb in Non-Autoimmune-Prone and SLE-Prone Mice. J. Transl. Autoimmun., 4.","DOI":"10.1016\/j.jtauto.2020.100075"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2019-eular.4234","article-title":"FRI0176 phase 2, double-blind, randomized, placebo-controlled study of a reversible b cell inhibitor, XMAB\u00ae5871, in systemic lupus erythematosus (SLE)","volume":"78","author":"Merrill","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of Long-Lived Plasma Cells and Humoral Immunity in Individuals Responding to CD19-Directed CAR T-Cell Therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"ref_63","unstructured":"(2025, August 06). CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06839976."},{"key":"ref_64","unstructured":"(2025, August 06). REACT-01: Reversing Autoimmunity Through Cell Therapy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06465147."},{"key":"ref_65","unstructured":"(2025, August 06). A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06913608?cond=Myopathy%20in%20systemic%20lupus%20erythematosus&rank=9."},{"key":"ref_66","unstructured":"(2025, August 06). A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06544330."},{"key":"ref_67","unstructured":"(2025, August 06). A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05869955."},{"key":"ref_68","unstructured":"(2025, August 06). Comparison of B-Cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis (COMPARE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06475495."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/08916934.2010.509122","article-title":"Increased BCMA Expression in Lupus Marks Activated B Cells, and BCMA Receptor Engagement Enhances the Response to TLR9 Stimulation","volume":"44","author":"Kim","year":"2011","journal-title":"Autoimmunity"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA Is Essential for the Survival of Long-Lived Bone Marrow Plasma Cells","volume":"199","author":"Raman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Guldenpfennig, C., Teixeiro, E., and Daniels, M. (2023). NF-KB\u2019s Contribution to B Cell Fate Decisions. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1214095"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase Directly Sheds the Survival Receptor BCMA from Plasma Cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Salazar-Camarena, D.C., Palafox-S\u00e1nchez, C.A., Cruz, A., Mar\u00edn-Rosales, M., and Mu\u00f1oz-Valle, J.F. (2020). Analysis of the Receptor BCMA as a Biomarker in Systemic Lupus Erythematosus Patients. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-63390-0"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0961203315608254","article-title":"Association of BAFF, APRIL Serum Levels, BAFF-R, TACI and BCMA Expression on Peripheral B-Cell Subsets with Clinical Manifestations in Systemic Lupus Erythematosus","volume":"25","author":"Cruz","year":"2016","journal-title":"Lupus"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Sanges, S., Guerrier, T., Duhamel, A., Guilbert, L., Hauspie, C., Largy, A., Balden, M., Podevin, C., Lef\u00e8vre, G., and Jendoubi, M. (2022). Soluble Markers of B Cell Activation Suggest a Role of B Cells in the Pathogenesis of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.954007"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40291-024-00730-0","article-title":"The Future of CAR T Therapeutics to Treat Autoimmune Disorders","volume":"28","author":"Pecher","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Dabkowska, A., Domka, K., and Firczuk, M. (2024). Advancements in Cancer Immunotherapies Targeting CD20: From Pioneering Monoclonal Antibodies to Chimeric Antigen Receptor-Modified T Cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1363102"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/pr.109.002006","article-title":"Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases","volume":"63","author":"Engel","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2147\/JIR.S282691","article-title":"Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction","volume":"14","author":"Fragoulis","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00296-019-04357-x","article-title":"Targeting Very Early Systemic Sclerosis: A Case-Based Review","volume":"39","author":"Melissaropoulos","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-Generation Anti-CD20 Monoclonal Antibodies in Autoimmune Disease Treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmun. Highlights"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Tan Su Yin, E., Hu, Y.X., and Huang, H. (2022). The Breakthrough and the Future: CD20 Chimeric Antigen Receptor T-cell Therapy for Hematologic Malignancies. ImmunoMedicine, 2.","DOI":"10.1002\/imed.1039"},{"key":"ref_84","unstructured":"(2025, August 06). A Phase 1 Study of ADI-001 in Autoimmune Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06375993."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3109\/08830180109045588","article-title":"CD19, CD21, and CD22: Multifaceted Response Regulators of B Lymphocyte Signal Transduction","volume":"20","author":"Poe","year":"2001","journal-title":"Int. Rev. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.coi.2005.03.005","article-title":"The Role of CD22 and Other Inhibitory Co-Receptors in B-Cell Activation","volume":"17","author":"Nitschke","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1074-7613(00)80339-8","article-title":"Tuning Antigen Receptor Signaling by CD22: Integrating Cues from Antigens and the Microenvironment","volume":"6","author":"Cyster","year":"1997","journal-title":"Immunity"},{"key":"ref_88","unstructured":"(2025, August 06). A Study of LCAR-AIO in Subjects with Relapsed\/Refractory Systemic Lupus Erythematosus, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06653556."},{"key":"ref_89","unstructured":"(2025, August 06). A Study of LCAR-AIO in Subjects with Relapsed\/Refractory Autoimmune Diseases. Available online: https:\/\/asgct.careboxhealth.com\/en-US\/trial\/listing\/583155."},{"key":"ref_90","unstructured":"(2025, August 06). Study of BCMA\/CD70 CAR-T Therapy for Refractory CSLE, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06934447?term=AREA%5BConditionSearch%5D(car%20t%20therapy)%20AND%20AREA%5BBasicSearch%5D(single%20arm)&rank=9."},{"key":"ref_91","unstructured":"(2025, August 06). Universal CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06946485."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/CCO.0000000000000983","article-title":"T-Cell Redirecting Bispecific and Trispecific Antibodies in Multiple Myeloma beyond BCMA","volume":"35","author":"Verkleij","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific Antibodies and CAR-T Cells: Dueling Immunotherapies for Large B-Cell Lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Melero, S., Hassouneh, F., Vallejo-Berm\u00fadez, I.M., Ag\u00fcera-Morales, E., Solana, R., and Caballero-Villarraso, J. (2025). Tandem CAR-T Cell Therapy: Recent Advances and Current Challenges. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1546172"},{"key":"ref_95","unstructured":"(2025, August 06). FKC288 in Participants With Autoimmune Kidney Diseases, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06285279."},{"key":"ref_96","unstructured":"(2025, August 06). CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and PSS-PAH: A Single-Center, Open, Non-Randomized, Single-Arm Clinical Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06947460."},{"key":"ref_97","unstructured":"(2025, August 06). US Zamto-Cel Autoimmune Diseases, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06708845."},{"key":"ref_98","unstructured":"(2025, August 06). CD19\/BCMA CAR-T Cell Therapy for Refractory\/Relapsed Lupus Nephritis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06785519?cond=lupus&term=CAR-T&rank=10."},{"key":"ref_99","unstructured":"(2025, August 06). BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06794008?cond=IgG4-related%20ophthalmic%20disease&viewType=Table&rank=7."},{"key":"ref_100","unstructured":"(2025, August 06). Efficacy of AZD0120 in Adults with Refractory SLE, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06897930?term=AREA%5BBasicSearch%5D(antigen%20specific%20systemic%20lupus)&rank=1."},{"key":"ref_101","unstructured":"(2025, August 06). UCAR T-Cell Therapy Targeting CD19\/BCMA in Patients With r\/r Systemic Lupus Erythematosus, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06920433?cond=%22Systemic%20lupus%20erythematosus%22&rank=10."},{"key":"ref_102","unstructured":"(2025, August 06). T Cell Therapy for Refractory Autoimmune Disease, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT07052565?cond=T%20Cell%20Therapy%20for%20Refractory%20Autoimmune%20Disease&rank=2."},{"key":"ref_103","unstructured":"(2025, August 06). JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06567080?cond=JWCAR201%20for%20the%20Treatment%20of%20Hematology%20Malignancy%20and%20Autoimmune%20Diseases&rank=1."},{"key":"ref_104","unstructured":"(2025, August 06). A Study of GC012F Injection in Subjects with Refractory Systemic Lupus Erythematosus, Available online:  https:\/\/www.clinicaltrials.gov\/study\/NCT06530849?term=AREA%5BBasicSearch%5D(GC012F)&rank=7."},{"key":"ref_105","unstructured":"(2025, August 06). An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases (SCAR02), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06503224?cond=An%20Exploratory%20Clinical%20Study%20of%20SCAR02%20Targeting%20BCMA%20and%20CD19%20for%20the%20Treatment%20of%20Refractory%20Autoimmune%20Diseases%20(SCAR02)&rank=1."},{"key":"ref_106","unstructured":"(2025, August 06). Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06497361?term=AREA%5BBasicSearch%5D(AREA%5BConditionSearch%5D(IgG4-related%20disease%20OR%20%22IgG4-RD%22%20OR%20%22%20IgG4-related%20sclerosing%20disease%22%20OR%20%22%20IgG4-related%20systemic%20disease%22%20OR%20%22%20Immunoglobulin%20G4-related%20sclerosing%20disease%22)%20AND%20AREA%5BOverallStatus%5D(NOT_YET_RECRUITING%20OR%20RECRUITING))&rank=10."},{"key":"ref_107","unstructured":"(2025, August 06). IMPT-514 in Systemic Lupus Erythematosus, Anca-Associated Vasculitis, and Idiopathic Inflammatory Myopathy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06462144."},{"key":"ref_108","unstructured":"(2025, August 06). Sequential CAR-T Cells Targeting BCMA\/CD19 in Patients with Relapsed\/Refractory Autoimmune Diseases (BAH247), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06428188."},{"key":"ref_109","unstructured":"(2025, August 06). Anti-CD19-CD3E-CAR-T Cells in Relapsed\/Refractory Autoimmune Disease, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06373081."},{"key":"ref_110","unstructured":"(2025, August 06). Fourth-Gen CAR T Cells Targeting BCMA\/CD19 for Refractory Systemic Lupus Erythematosus (SLE) (BAH242), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06350110."},{"key":"ref_111","unstructured":"(2025, August 06). CD19\/BCMA CAR-T Cell Therapy for Refractory\/Moderate-to-Severe Systemic Lupus Erythematosus, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06349343."},{"key":"ref_112","unstructured":"(2025, August 06). Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05858684?cond=car-t&viewType=Table&rank=5."},{"key":"ref_113","unstructured":"(2025, August 06). Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06947473?cond=Peeling%20skin%20syndrome%20OR%20%22deciduous%20skin%22%20OR%20%22%20familial%20continuous%20skin%20peeling%20syndrome%22%20OR%20%22%20idiopathic%20deciduous%20skin%22%20OR%20%22%20keratosis%20exfoliativa%20congenita%22%20OR%20%22%20peeling%20skin%20disease%22%20OR%20%22%20PSS%22&aggFilters=status:not%20rec&viewType=Table&rank=8."},{"key":"ref_114","unstructured":"(2025, August 06). Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06548607?term=AAV&cond=%22Xerostomia%22&viewType=Table&rank=4."},{"key":"ref_115","unstructured":"(2025, August 06). A Study of CD19\/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients with Refractory Sjogren\u2019s Syndrome, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05085431."},{"key":"ref_116","unstructured":"(2025, August 06). CAR T-Cell Therapy Targeting CD19 and BCMA in Patients with Relapse\/Refractory Autoimmune Diseases, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06941129?term=AREA%5BConditionSearch%5D(%22Inclusion%20Body%20Myositis%22)%20AND%20AREA%5BInterventionSearch%5D(%22vaccines%22)&rank=1."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Tzannou, I., Batsis, I., Tsonis, I., Liga, M., Gkirkas, K., Ximeri, M., Dolgyras, P., Bampali, V., and Evangelidis, P. (2024). EASIX and M-EASIX Predict Severe Cytokine Release Syndrome and Overall Survival after CAR T-Cell Therapy. Blood Vessel. Thromb. Hemost., 1.","DOI":"10.1016\/j.bvth.2024.100025"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/16\/1242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:25:45Z","timestamp":1760034345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/16\/1242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":117,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cells14161242"],"URL":"https:\/\/doi.org\/10.3390\/cells14161242","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}